MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents.
about
Epigenetic changes of DNA repair genes in cancerO6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patientsComprehensive genomic characterization defines human glioblastoma genes and core pathwaysMouse models of liver cancer: Progress and recommendationsBiomarkers for glioma immunotherapy: the next generationO(6)-methylguanine-DNA methyltransferase in glioma therapy: promise and problemsDNA methylation biomarkers: cancer and beyondTherapy-related myeloid neoplasms - what have we learned so far?Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA-repair gene MGMT and sensitizes the cells to alkylating agentsTherapy-related myeloid neoplasms: pathobiology and clinical characteristicsDNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancerHuman monocytes undergo excessive apoptosis following temozolomide activating the ATM/ATR pathway while dendritic cells and macrophages are resistantRational incorporation of selenium into temozolomide elicits superior antitumor activity associated with both apoptotic and autophagic cell deathNSC666715 and Its Analogs Inhibit Strand-Displacement Activity of DNA Polymerase β and Potentiate Temozolomide-Induced DNA Damage, Senescence and Apoptosis in Colorectal Cancer CellsGenome-wide analysis of alternative splicing in Volvox carteriHigh-throughput data integration of RNA-miRNA-circRNA reveals novel insights into mechanisms of benzo[a]pyrene-induced carcinogenicityNRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cellsDNA repair modulates the vulnerability of the developing brain to alkylating agentsThe identification of a novel gene, MAPO2, that is involved in the induction of apoptosis triggered by O⁶-methylguanineTreatment of recurrent malignant gliomas with fotemustine monotherapy: impact of dose and correlation with MGMT promoter methylationDNA polymorphism and risk of esophageal squamous cell carcinoma in a population of North Xinjiang, China.Polymorphisms in DNA repair genes and MDR1 and the risk for non-Hodgkin lymphoma.Quercetin abrogates chemoresistance in melanoma cells by modulating deltaNp73.Nuclear reorganization of DNA mismatch repair proteins in response to DNA damage.Interactions of human mismatch repair proteins MutSalpha and MutLalpha with proteins of the ATR-Chk1 pathway.Age and sex dependent changes in liver gene expression during the life cycle of the rat.Inducible Protective Processes in Animal Systems XIII: Comparative Analysis of Induction of Adaptive Response by EMS and MMS in Ehrlich Ascites Carcinoma CellsRelevance of DNA repair gene polymorphisms to gastric cancer risk and phenotypeRedox regulation of DNA repair: implications for human health and cancer therapeutic development.O-methylguanine-DNA methyltransferase (MGMT) mRNA expression predicts outcome in malignant glioma independent of MGMT promoter methylation.Fission yeast Hsk1 (Cdc7) kinase is required after replication initiation for induced mutagenesis and proper response to DNA alkylation damage.Polymorphisms of the DNA repair gene MGMT and risk and progression of head and neck cancer.Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors.Acetylation of Werner syndrome protein (WRN): relationships with DNA damage, DNA replication and DNA metabolic activities.Targeting DNA repair pathways for cancer treatment: what's new?Repair of endogenous DNA base lesions modulate lifespan in miceRad51 and BRCA2--New molecular targets for sensitizing glioma cells to alkylating anticancer drugs.Altered methylation of the DNA repair gene MGMT is associated with neural tube defects.Both base excision repair and O6-methylguanine-DNA methyltransferase protect against methylation-induced colon carcinogenesis
P2860
Q22242858-6F84A836-FCAA-4D81-A8B2-C5B46DA93698Q24607903-D279EE18-32D3-45CB-AFAF-629BE57B7B70Q24656128-3CA8E0B1-5FE5-4087-BAA3-1FD905D640F7Q26799788-381E985F-C572-4D3F-84E0-9F30CB71EAD4Q26825496-B74AC9A5-93C3-4074-9A7B-E04877A23AD1Q26853112-C9384DEE-98FA-43E6-B0FD-678C09AE0451Q26996421-CFF2EAC0-C9BB-4671-AFF8-92A62AD5F855Q28071318-16E34505-56C0-44D6-B4AA-EEC422EDFD51Q28273012-8B059C69-2F51-454F-B3FB-4A96C8B2061CQ28386366-B79ECDF3-2664-493F-B4B5-7AFF192C5685Q28477059-40517D4A-EF27-4A26-8362-50852B3DA8BCQ28480882-0B207023-03B8-48D5-B3FE-E43335C1B015Q28482143-DC05EC4D-E687-4001-814C-9224CF651903Q28546932-9FB70582-AAC4-4616-9958-BA7CC40FB632Q28651125-1FB13C2E-3607-4C05-BA32-284472967240Q28652466-8F9869E6-EEB7-425D-B3AD-64FA4B0E7C1FQ29247923-A8A0FA53-11D1-4631-9161-DDADC0E0F7F5Q30488029-6AFE9AF0-4E78-4DF2-8800-45C8E06A84FAQ32884511-7BFBC4B8-EC4F-4A13-8C31-87066F501A66Q33383951-8EEE61EC-2AC3-488E-BDC1-FFD9E8793505Q33529216-096DA655-11D0-460C-BC1E-FFFFD0D990A9Q33580765-D919D286-E9E2-4767-9289-5D8C2ECE8A1CQ33601945-F9971231-277D-4169-9BB7-B099EDD0630DQ33643516-51E01249-B494-460F-8D97-66DE815D3254Q33648599-4FC9F410-8B89-472E-B9D6-7254AFFFB1D5Q33758968-3136E8CD-C535-4966-AB3B-329F5F48461AQ33791896-AF608303-38FC-4D80-8155-9373629F4341Q33829340-7833F4DF-F91C-4AAE-8919-6208AD6D64A4Q33830130-5F6048B3-A9E8-4818-BA7A-B57DF96BB33DQ33834163-078842C5-27F4-42A1-B646-1C9C194B4331Q33853216-C857695B-CD5D-4C29-B827-D8EAF824CA63Q33904061-09551E22-3A01-4B04-A29B-82E94A1CFC2BQ33953822-8404043C-960B-4CC4-9078-F7268581CBC7Q33958963-0F494C42-D57C-4A5A-97E5-0A42F75CBA0BQ34004402-092127B1-37BB-4F63-8726-9DB0C0D6061DQ34015040-973E601F-F1DE-4E05-AD9C-5DFF1205E775Q34016965-3E078F22-7D7C-466D-9CF5-E3C217005A8CQ34071842-A2AB778C-721A-4042-949A-561366D222C1Q34078985-6AB286C2-EF47-4EB1-9A01-85F0225AC61CQ34132791-33D6E2D2-0D8C-4FAA-871E-2548CC75E7F7
P2860
MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
MGMT: key node in the battle a ...... induced by alkylating agents.
@ast
MGMT: key node in the battle a ...... induced by alkylating agents.
@en
MGMT: key node in the battle a ...... induced by alkylating agents.
@nl
type
label
MGMT: key node in the battle a ...... induced by alkylating agents.
@ast
MGMT: key node in the battle a ...... induced by alkylating agents.
@en
MGMT: key node in the battle a ...... induced by alkylating agents.
@nl
prefLabel
MGMT: key node in the battle a ...... induced by alkylating agents.
@ast
MGMT: key node in the battle a ...... induced by alkylating agents.
@en
MGMT: key node in the battle a ...... induced by alkylating agents.
@nl
P2093
P1433
P1476
MGMT: key node in the battle a ...... induced by alkylating agents.
@en
P2093
Bernd Kaina
Markus Christmann
Steffen Naumann
Wynand P Roos
P304
P356
10.1016/J.DNAREP.2007.03.008
P577
2007-05-07T00:00:00Z